No US national data are available on the prevalence and correlates of DSM-5-defined major depressive disorder (MDD) or on MDD specifiers as defined in . OBJECTIVE To present current nationally representative findings on the prevalence, correlates, psychiatric comorbidity, functioning, and treatment of DSM-5 MDD and initial information on the prevalence, severity, and treatment of DSM-5 MDD severity, anxious/distressed specifier, and mixed-features specifier, as well as cases that would have been characterized as bereavement in DSM-IV. RESULTS Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively. Odds of 12-month MDD were significantly lower in men (OR, 0.5; 95% CI, 0.46-0.55) and in African American (OR, 0.6; 95% CI, 0.54-0.68), Asian/Pacific Islander (OR, 0.6; 95% CI, 0.45-0.67), and Hispanic (OR, 0.7; 95% CI, 0.62-0.78) adults than in white adults and were higher in younger adults (age range, 18-29 years; OR, 3.0; 95% CI, 2.48-3.55) and those with low incomes ($19 999 or less; OR, 1.7; 95% CI, 1.49-2.04). Associations of MDD with psychiatric disorders ranged from an aOR of 2.1 (95% CI, 1.84-2.35) for specific phobia to an aOR of 5.7 (95% CI, 4.98-6.50) for generalized anxiety disorder. Associations of MDD with substance use disorders ranged from an aOR of 1.8 (95% CI, 1.63-2.01) for alcohol to an aOR of 3.0 (95% CI, 2.57-3.55) for any drug. Most lifetime MDD cases were moderate (39.7%) or severe (49.5%). Almost 70% with lifetime MDD had some type of treatment. Functioning among those with severe MDD was approximately 1 SD below the national mean. Among 12.9% of those with lifetime MDD, all episodes occurred just after the death of someone close and lasted less than 2 months. The anxious/distressed specifier characterized 74.6% of MDD cases, and the mixed-features specifier characterized 15.5%. Controlling for severity, both specifiers were associated with early onset, poor course and functioning, and suicidality.
One specifier indicates MDD episodes associated with anxious distress. A second indicates "mixed" MDD episodes (ie, accompanied by manic or hypomanic features not meeting criteria for a bipolar disorder). These specifiers have been studied in patients [20] [21] [22] [23] but not national data; the proportion of MDD cases diagnosed as positive after bereavement has also not been studied. The DSM-IV and DSM-5 include a severity specifier (mild, moderate, or severe) not previously examined in national data. Furthermore, DSM-5 removed the DSM-IV MDD exclusion criterion for bereavement. While DSM-5 does not include bereavement as a new MDD specifier, exploring the potential influence of this change on national rates of DSM-5 MDD by identifying the proportion of MDD cases that would have been excluded as bereavement under DSM-IV rules is of considerable interest. The National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III) is a nationally representative 2012-2013 survey of DSM-5 psychiatric and SUDs in adults 18 years or older, including MDD and the specifiers described above. Herein, we report NESARC-III findings on the adult prevalence, sociodemographic and clinical correlates, disability, course, and treatment for 12-month and lifetime DSM-5 MDD, as well as on the specifiers and bereavement.
Methods

Sample and Procedures
The NESARC-III target population was the US noninstitutionalized civilian population aged at least 18 years, including household and selected group quarter residents (eg, group homes and dormitories). Probability sampling was used to select respondents. 24 Primary sampling units were counties or groups of counties, secondary sampling units (SSUs) were groups of US Census-defined blocks, and tertiary sampling units were households within SSUs; within households, eligible adults were randomly selected. African American, Asian, and Hispanic adults were oversampled; in households with at least 4 eligible racial/ethnic minority individuals, 2 were selected (n = 1661). The sample size was 36 309. The total response rate was 60.1%. Data were collected from April 2012 to June 2013 and were analyzed in 2016-2017.
Data were adjusted for oversampling and nonresponse and weighted to represent the US civilian population based on the 2012 American Community Survey. 25 Weighting adjustments compensated for nonresponse. 24 Comparing participants with the total eligible sample (including nonrespondents), no significant differences were found in percentages of African American, Asian, or Hispanic individuals or in population density, vacancy rate, or proportion in group quarters or renters.
Compared with the eligible sample, respondents included slightly different percentages of men (46.2% vs 48.1%) and those aged 30 to 39 years (17.4% vs 16.7%), 40 to 49 years (18.3% vs 18.1%), and 60 to 69 years (12.6% vs 13.7%), respectively.
24
The sample sociodemographic characteristics are reported elsewhere.
Interviewer field methods and quality control included structured training, supervision, and random respondent verification callbacks, as previously reported. 24 Oral informed consent was recorded, and respondents received $90. The National Institutes of Health and Westat, Inc (NESARC-III contractor) institutional review boards approved the protocols.
DSM-5 Diagnostic Interview
The National Institute on Alcohol Abuse and Alcoholism
DSM-5 version of the Alcohol Use Disorder and Associated Disabilities Interview Schedule 5 (AUDADIS-5)
26,27 was used.
This fully structured interview for lay interviewers was used to measure DSM-5 mood, anxiety, substance use, and personality disorders.
DSM-5 MDD
Major depressive episode was diagnosed when at least 2 weeks of persistent depressed mood, anhedonia, or hopelessness occurred (reported by self or observed by others), plus additional symptoms from criterion A, for a total of 5 of the 9 DSM-5 major depression criteria 26 and the clinical significance criterion. Lifetime DSM-5 MDD was defined as at least one lifetime major depressive episode without full DSM-5 manic, mixed, or hypomanic episodes, 26,28 excluding substanceinduced and medical-induced disorders. Those with at least one episode in the prior 12 months were classified as having 12-month MDD.
Key Points
Question What is the national prevalence of DSM-5 major depressive disorder, the DSM-5 anxious/distressed and mixed-features specifiers, and their clinical correlates?
Findings In this national survey of 36 309 US adults, the 12-month and lifetime prevalences of major depressive disorder were 10.4% and 20.6%, respectively, with most being moderate (6-7 symptoms) or severe (8-9 symptoms) and associated with comorbidity and impairment. The anxious/distressed specifier characterized 74.6% of major depressive disorder cases, and the mixed-features specifier characterized 15.5%; almost 70% with lifetime major depressive disorder received some type of treatment.
Meaning Major depressive disorder remains a serious US health problem, with much to be learned about its specifiers.
In a test-retest study 26 
DSM-5 MDD Specifiers
Severity Specifier The DSM-5 does not state the number of MDD symptoms required for each severity level, so these levels were defined as follows: mild is 5 symptoms (minimum for a diagnosis), moderate is 6 to 7 symptoms, and severe is 8 to 9 symptoms. The DSM-5 also states that distress and impairment should increase across levels but without clear definitions. Therefore, we used the symptom count only, which is clear. The symptom count was based on the lifetime MDD episode when mood or anhedonia was the worst.
Anxious/Distressed Specifier
The DSM-5 defines this specifier as at least 2 of the following 5 anxiety or distress symptoms during an episode: feeling keyed up or tense, being unusually restless, having trouble concentrating due to worry, fearing something awful would happen, and thinking one might lose control of oneself. These symptoms were required for at least 2 weeks during the episode when mood or anhedonia was the worst (a lesser threshold than the actual DSM-5 definition, which requires symptoms on more days than not).
Mixed-Features Specifier
The DSM-5 defines this specifier as at least 3 of the following symptoms during episodes not meeting criteria for mania or hypomania: elevated or expansive mood, inflated self-esteem or grandiosity, unusual talkativeness or pressure to keep talking, flight of ideas or racing thoughts, increased energy or goaldirected activity, involvement in activities (eg, financial or sexual) with potential for painful consequences, and decreased need for sleep (rested despite sleeping less). These symptoms were required for most days during at least one lifetime episode.
Bereavement
Bereavement is not a DSM-5 specifier, and cases of bereavement were not excluded in estimates of MDD reported herein. However, participants meeting criteria for DSM-5 MDD were coded positive on a variable representing bereavement if all MDD episodes began just after someone close died and lasted less than 2 months, consistent with DSM-IV and previous reports.
32
Other Psychiatric Disorders
The AUDADIS-5 DSM-5 anxiety disorder diagnoses (panic, agoraphobia, social phobia, specific phobia, and generalized anxiety disorder) excluded substance-induced and medicalinduced disorders, consistent with DSM-5. The DSM-5 posttraumatic stress disorder (PTSD) generally followed the DSM-5 definition, but criteria C and D more strictly required at least 3 positive criteria rather than at least 2 positive criteria. Test-retest reliability of these diagnoses was fair to good (κ = 0.35-0.54), 26 with higher reliability for associated DSM-5 dimensional scales (ICC, 0.50-0.79). 26 Clinical validity (concordance with PRISM-5) was fair to good (κ = 0.20-0.59) and was greater for corresponding dimensional scales (ICC, >0.53 for all). 30 The DSM-5 schizotypal, borderline, and antisocial personality disorders were assessed as defined in DSM-IV, as described previously. to take the sample design into account, were considered statistically significant when 95% CIs excluded 1.00.
Results
DSM-5 MDD Prevalence and Sociodemographic Correlates
Of the 36 309 adult participants in NESARC-III, the 12-month and lifetime prevalences of DSM-5 MDD were 10.4% and 20.6%, respectively ( 
Associations With Other Psychiatric Disorders
All disorders were significantly associated with 12-month and lifetime MDD ( Table 2 ). The aORs were larger for drug use disorder than for alcohol or nicotine use disorders and were larger for borderline than other personality disorders. Additional adjustment for other psychiatric disorders decreased all aORs (some substantially), but most remained significant.
MDD Characteristics
As summarized in Table 3 , the mean (SE) age at onset of MDD was 29.05 (0.21) years. Overall, a mean (SE) of 3.86 (0.10) lifetime episodes were reported. The median duration of lifetime longest or only episode was 25.9 weeks.
Treatment
Treatment for MDD was reported by 69.4% of participants with a lifetime MDD diagnosis (Table 3) ; 53.1% reported using medication, 62.5% reported talking with a professional, 14.9% reported receiving nonprofessional support (ie, self-help or support group, hotline, or internet chat room), 10.2% reported going to an emergency department, and 11.8% reported being hospitalized overnight or longer. The mean age at first treatment for MDD was 32.0 years, resulting in a mean delay from onset to first treatment of 47.5 months. While the prevalence of different types of treatment was lower among those whose only MDD was within the past 12 months, more than 50% of these received some type of treatment for MDD.
Suicidality
During the lifetime MDD episode when mood or anhedonia was at its worst, 34.8% thought about their own death, 46.7% wanted to die, and 39.3% contemplated suicide; among those with MDD only within the past year, 28.8%, 32.1%, and 22.8% had these thoughts, respectively (Table 3 ). Lifetime and past-year suicide attempts were reported by 13.6% and 4.8%, respectively. 
Functioning
DSM-5 Specifiers and Bereavement
When mood or anhedonia was at its worst during lifetime MDD ( Table 5 lists clinical correlates of the anxious/distressed specifier and the mixed-features specifier. Both specifiers were significantly associated with earlier onset, number of episodes, longest duration, severity, MDD treatment overall and by type, suicidality, and poorer SF-12v2 scores. Most of these correlates remained significant when controlling for sociodemographic characteristics and MDD severity.
Discussion
In 2012-2013, over 10% of US adults experienced DSM-5 MDD in the prior 12 months, and over 20% experienced lifetime DSM-5 MDD. Major depressive disorder was associated with other psychiatric disorders, especially generalized anxiety disorder and borderline personality disorder, associations found in previous studies.
5,46-49 On average, episodes lasted more than 6 months. This study found association between low income and 12-month MDD, consistent with other studies conducted within the last 3 years. 1, 57, 58 While this association could be due to depression-impaired functioning leading to lower income, the increases in depression and suicide that have accompanied growing income inequality suggest that the relationship of low income to MDD is due to stress from inadequate financial resources for life necessities or pessimism about improved future prospects. 1 If so, while treatment can benefit those with MDD, prevention may require change in larger societal processes.
59,60
Major depressive disorder was associated with anxiety disorders, particularly panic disorder and generalized anxiety disorder, as well as with PTSD. Associations were strongest with models adjusting only for sociodemographic characteristics. Further adjusting for psychiatric comorbidity reduced associations by a factor of approximately 50%, although ORs remained statistically significant. These findings reflect the underlying association of anxiety disorders with each other and MDD within the internalizing component of the transdiagnostic spectrum. 61 Major depressive disorder was associated with SUDs, particularly drug disorders, as found previously for cannabis, 40,62 nonmedical prescription opioids, 5,57,63 and drug use disorders. 41 With increasingly positive attitudes toward substance use [64] [65] [66] and increasing rates of adult SUDs 76, 77 ; prospectively, cannabis worsens the course of depressive disorders. 78 The likelihood of treatment for depression is reduced in those with SUDs. 79 However, dual-focused treatment is more effective when 2 disorders are present. 70 Therefore, clinician education and training in dual-disorder screening and treatment should be prioritized. Of participants with lifetime DSM-5 MDD, 69.4% received any treatment for their disorder, slightly higher than in the 2001-2002 NESARC (60.6%). 5 This result is higher than the treatment rate in one recent study 80 that used less specific measures to identify depression but is consistent with rates from other studies published in the last 4 years. 81, 82 The NESARC-III treatment rates are plausible given the extent of direct-toconsumer advertising of antidepressants 83 and widespread distribution through primary care. 79 However, with 30% of patients still untreated, improved treatment delivery for MDD remains needed; much distress or social or economic burden is avoidable through behavioral and pharmacologic MDD treatment. 12, 84 Studies should examine the demographic and clinical correlates of treatment and whether these factors are changing over time. This study contributes novel information about the epidemiology of 2 new DSM-5 major depression specifiers. That almost three-quarters of those with MDD had the anxious/ distressed specifier confirms clinical observation and research. 46 We also provide the first nationally representative information on demographic and clinical correlates of these specifiers. In patient samples, the anxious/distressed specifier predicts a poor course of MDD. 20,21 Clearly, more information on both specifiers is needed.
Limitations
This study has limitations. The study was cross-sectional; associations do not necessarily indicate causal relationships. Lifetime associations of MDD with other psychiatric disorders may be influenced by recall bias, although this possibility is less likely for 12-month findings, which were similar. Some groups were not included (eg, homeless and prisoners), so NESARC-III may underestimate MDD prevalence. Also, as noted, 85 DSM-5 left differentiating MDD from normal bereavement to clinical judgment. The NESARC-III interviews were conducted by lay interviewers, precluding clinical judgments. Therefore, all cases of MDD beginning shortly after the a Dichotomous row variables were modeled with logistic regression. Continuous row variables were modeled with linear or log-linear regression.
b During the lifetime episode when mood or anhedonia was at its worst.
c Mixed features do not meet full criteria for either mania or hypomania and could characterize any MDD episode.
d Crude association.
e Controls for sociodemographic variables (sex, race/ethnicity, age, marital status, educational level, family income, urbanicity, and region).
f Controls for sociodemographic variables (sex, race/ethnicity, age, marital status, educational level, family income, urbanicity, and region) and severity (mild, moderate, or severe).
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers
Original Investigation Research death of someone close and remitting in less than 2 months were characterized as bereavements, as was done in previous research. 32 Other studies with relevant data could explore other bereavement definitions. Our definition of the anxious/ distressed specifier used a lower threshold than DSM-5, which may have somewhat inflated the rates, an issue meriting future study using different data. AUDADIS-5 used a slightly different algorithm for PTSD than the final DSM-5 definition, caused by a last-minute DSM-5 change that occurred too late to implement in NESARC-III. Furthermore, we defined the DSM-5 severity specifier by MDD symptom counts, which are straightforward, transparent, and replicable. This approach enabled us to examine the association between these severity levels and SF-12v2 impairment scores. The DSM-5 also suggests incorporation of distress and impairment levels into the severity classifications but defines these vaguely. Future studies should develop brief, psychometrically sound measures of these domains for epidemiologic studies. Also, a response rate greater than 60.1% would be preferable. However, NESARC-III response rates compare favorably with other recent national health surveys. [86] [87] [88] Finally, methodological studies addressing the addition of hopelessness and symptoms observed by others but not subjectively experienced would contribute useful information, as would future surveys using DSM-5 footnotes to MDD on bereavement to develop a new bereavement instrument or incorporating complicated grief measures (eg, those by Shear and colleagues). 89 These limitations are offset by the large sample, reliable and valid measures of psychiatric and substance disorders, and rigorous study methods. NESARC-III is also unique in providing current, comprehensive national information on DSM-5 MDD and its specifiers that is unavailable from any other source. The NESARC-III 12-month and lifetime MDD prevalences (10.4% and 20.6%, respectively) are higher than those of the 2001-2002 NESARC (5.3% and 13.2%, respectively). Increases between surveys can occur for many reasons, 90 
Conclusions
This study on MDD prevalence, demographic and psychiatric correlates, disability, treatment use, and specifiers can inform policymakers, clinicians, and the public, as well as stimulate investigation in several areas. While many with MDD receive treatment, others remain untreated. The high prevalence of MDD among US adults is a substantial concern given the personal, public health, and economic burdens that the disorder imposes. Therefore, the need to reduce the prevalence of this disorder remains. eAppendix. Supplementary Material The NESARC-III Clinical (Procedural) Validity Study: 712 blinded clinician re-appraisals of AUDADIS diagnoses.
The NESARC-III Clinical (Procedural) Validity Study has been described in detail in two previous publications 1, 2 . Readers are encouraged to consult these two publications for detailed information about the study. In these two publications, "clinical validity" was termed "procedural validity", consistent with earlier publications that have used these two terms interchangeably (e.g., [3] [4] [5] [6] ). Here, we summarize the clinical (procedural) validity study briefly below for the convenience of the readers of the present article.
Background. The ability of epidemiological studies to produce clinically meaningful diagnoses is critical to their credibility and utility for clinicians, researchers, and policymakers. Since clinicians cannot be used to make diagnoses in large-scale general population studies, diagnostic procedures administered by lay interviewers must be used. Thus, clinical (procedural) validation of lay-administered psychiatric diagnostic instruments is an important element of general population surveys. One way of establishing such validity is by comparing diagnoses generated by clinician re-appraisals of a series of participants to the diagnoses generated by the lay-administered interviews. Few clinical (procedural) validation studies of psychiatric disorders have been conducted in general population samples.
In a study conducted in the early 1980s, Diagnostic Interview Schedule (DIS) diagnoses were compared to structured psychiatrist re-interviews of Epidemiologic Catchment Area participants (n=370), with psychiatrists completely blinded to DIS interviews 7 . Complete blinding of the second assessor increases the independence of the second assessment from the first. Such independence is a desirable design feature if one is interested in clinician diagnoses that were not influenced by information from the initial interview. In this study, chance-corrected lay/psychiatrist concordance ranged for major depressive disorder ( =0.28-0.50) The PRISM is a semi-structured clinician-administered diagnostic interview that includes full separate modules to assess the diagnostic criteria in detail for unipolar and bipolar mood disorders, anxiety disorders (generalized anxiety, panic disorder, specific phobia, social anxiety), post-traumatic stress disorder, substance use disorders (DSM-IV abuse, dependence; DSM-5 substance use disorder) and personality disorders (e.g., antisocial, borderline). The PRISM was initially designed to overcome well-known challenges in assessing mood and anxiety disorders among drug users and heavy drinkers [9] [10] [11] . The PRISM was successful in accomplishing this purpose. Test-retest reliability of major depressive disorder was established in two studies conducted in patients who were all drug users or heavy drinkers. In these test-retest reliability studies, two interviewers conducted two separate interviews on a series of participants, with the second interviewer always completely blinded to the results of the first interview. These studies established that the PRISM had excellent test-retest reliability for current and lifetime major depressive disorder: =0.81 and =0.74, respectively 12 , and =0.75 and =0.70, respectively 13 . Further, a group independent of the PRISM developers conducted a validity study using the Longitudinal Expert All Data (LEAD) procedure (see Spitzer, 1983 14 for the design of LEAD studies). In this study, the PRISM demonstrated better validity than the SCID in diagnosing major depressive disorders in substance-using patients 15 .
The version of the PRISM used in the clinical (procedural) validity study was the PRISM-5. This version is computer-assisted to improve efficiency, and updated for DSM-5 criteria. To reduce participant burden for the clinical (procedural) validity study, two shortened versions of the PRISM-5 were prepared: one that included mood disorders but not anxiety disorders, and the other with anxiety disorders but not mood disorders. These two versions were randomly assigned to participants. Sample selection. After completing face-to-face AUDADIS-5 interviews for the NESARC-III, 777 participants were selected for the clinical validation study using an algorithm based on the AUDADIS-5 psychiatric and substance module screening questions designed to increase the prevalence of psychopathology. Participants were also required to reside within the Eastern Time Zone to facilitate telephone re-interviews from New York City, the location of the PRISM-5 interviewers. NIH, Westat and New York State Psychiatric Institute IRBs approved all procedures; all respondents gave informed consent to participate. The response rate was excellent, 92.5% (712/777).
Data collection. PRISM-5 clinical re-appraisals were conducted by telephone from a call center established in Dr. Hasin's research laboratory at New York State Psychiatric Institute, permitting centralized, closelysupervised interviewing of participants dispersed over a wide geographic area. These interviews were conducted after receiving notification from Westat that the participant's NESARC-III interview was complete. The mean interval between AUDADIS-5 and PRISM-5 interviews was 10.5 days (s.e. = 0.27); median was 9 days, and the range was 2−69 days. With consent, PRISM-5 interviews were recorded for quality assurance purposes. Of the 712 participants, 700 (98.3%) consented and their interviews were recorded.
Blinding procedures. All PRISM-5 team members (not just the interviewers) were completely blinded to AUDADIS-5 interview results, diagnoses and values in the selection algorithm. To ensure that participants knew this, and the reason for it, the PRISM-5 interviewer told each respondent at the beginning of the interview that the re-interview was to help understand the quality of the previous interview, and that he/she (the interviewer) did not have information from the previous interview. Participants were instructed to respond with "whatever answer seems right to you today. Don't try to make your answers the same as last time, or differentjust give the answer that seems right to you now." This procedure was designed to maximize the independence of AUDADIS-5 and PRISM-5 assessments.
PRISM-5 interviewers. The ten PRISM-5 interviewers for the clinical (procedural) validity all had master's degrees in clinical fields. In addition, they all had clinical experience with psychiatric and/or substance abuse patients (mean length of clinical experience, 4.15 years, range, 2-14 years).
PRISM-5 trainer/supervisors. Training on PRISM-5, study procedures and confidentiality was conducted by two PRISM trainer/supervisors (Christina Aivadyan, M.S., and Eliana Greenstein, M.A., M.P.H.). These two trainer/supervisors were co-authors of the NESARC-III clinical (procedural) validity study 1, 2 . They both have a master's degree in a clinical field, clinical experience with psychiatric and substance abuse patients, and many years of experience managing research studies and training and supervising clinician-and lay-administered diagnostic interviewers for research studies in clinical and general population settings in the U.S. and elsewhere (e.g., Spain, Norway, Israel).
PRISM-5-training/certification. After reviewing a training manual and answering self-study questions, the PRISM-5 trainer/supervisors conducted 4 days of PRISM-5 training that included didactic presentation of material (covering confidentiality, how to engage participants, diagnostic criteria, managing the computer), and extensive group role-plays to ensure that interviewers were familiar with the interview and also with techniques to conduct the interview efficiently while making participants feel at ease during the interview. Trainees were allowed to begin interviewing for the clinical validity study only after they were certified by the study trainer/supervisors. To certify trainees, the trainer/supervisors listened to five PRISM-5 interviews, and rated their quality using structured interview quality rating forms. Interview quality was required to be satisfactory or better. Thus, training was structured and rigorous.
PRISM-5 quality assurance. During the course of the study, the trainer/supervisors used the same structured interview quality rating forms to rate recordings from 214 randomly selected PRISM-5 interviews for quality assurance, using the information from these reviews to provide feedback to interviewers in regular group supervision meetings. Thus, quality assurance procedures were extensive. In addition, two psychiatrists who received PRISM-5 training, each with >10 years of clinical experience, independently reviewed 107 randomly selected PRISM-5 recordings. Of these, 59 were also reviewed by PRISM-5 supervisors. Among these 59 cases, 234 relevant mood and anxiety disorder diagnoses were possible. Of these mood and anxiety diagnoses, psychiatrists and supervisors agreed on 95.3% of them; 1.3% were made by a psychiatrist but not a supervisor, while 3.4% were made by a supervisor but not a psychiatrist. Thus, the excellent agreement between the two study trainer/supervisors and the psychiatrists further attests to the excellent level of supervision/quality control of the clinical (procedural) validity study.
